Treatment of giardiasis: current status and future directions
Richard R Watkins1, Lars Eckmann
1Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, OH, USA, richard.watkins@akrongeneral.org.
Abstract:
Giardiasis is a common yet neglected cause of diarrheal illness worldwide. Antimicrobial therapy is usually but not always effective and drug resistance has become an increasing concern. Several promising drug candidates have been recently identified that can overcome antibiotic resistance in Giardia. These include derivatives of 5-nitroimidazoles and benzimidazoles, as well as hybrid compounds created from combinations of different antigiardial drugs. High-throughput screening of large compound libraries has been a productive strategy for identifying antigiardial activity in drugs already approved for other indications, e.g. auranofin. This article reviews the current treatment of giardiasis, mechanisms of resistance, advances in drug and vaccine development, and directions for further research on this significant human pathogen.
More Related Videos
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Anthelminthic Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Fungal Phylum Microsporidia
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy


